...A. So for the time frame in which we -- for our medium-term outlook, we are -- we believe that we can outgrow the market, which may grow at 4% to 6% by 200 to 300 bps per year. B. This year, with the midpoint of our guidance at 10%, we would be higher than that. C. Last year that was approximately 2 and 3 years ago, we grew 19%, although that was partly a recovery from the COVID year 2020. D. We expect to see, as Gerald will give you more details that we will also not only be able to grow our revenue, and despite our very significant roughly 10% R&D investment to seize the historic large secular megatrends in spatial biology and proteomics, and to some extent, even in artificial intelligence for our semiconductor business, but we're not going to focus on that today. E. So despite that very significant R&D investment, that is a good 3% or so above the peer average. F. We expect to make further progress into the low 20% -- 20s% operating margin, and we expect to deliver double-digit non-GAAP...
